Search

Displaying results 7891 - 7900 of 10000 in total
  1. Drug

    Necuparanib

    go.drugbank.com/drugs/DB16251
    Investigational

    Necuparanib is under investigation in clinical trial NCT01621243 (M402 in Combination With Nab-paclitaxel and Gemcitabine in Pancreatic Cancer).

  2. Drug

    ABX-196

    go.drugbank.com/drugs/DB16339
    Investigational

    ABX-196 is under investigation in clinical trial NCT03897543 (ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma).

  3. Drug

    Tersolisib

    go.drugbank.com/drugs/DB21752
    Investigational

    STX-478 is under investigation in clinical trail NCT05768139 (First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

  4. Drug

    Cefpirome

    go.drugbank.com/drugs/DB13682
    Approved

    Cefpirome is a β-lactam or cephalosporin.[A249055]

  5. Drug

    Cefacetrile

    go.drugbank.com/drugs/DB01414
    InvestigationalVet approved

    A derivative of 7-aminocephalosporanic acid.

  6. Drug

    KC706

    go.drugbank.com/drugs/DB05157
    Investigational

    KC706 is a novel anti-inflammatory drug that works by inhibiting the activity of p38 MAP kinase.

  7. Drug

    Amelubant

    go.drugbank.com/drugs/DB06248
    Investigational

    Synonyms: Carbamic acid, N-[[4-[[3-[[4-[1-(4-hydroxyphenyl)-1-methylethyl]phenoxy]methyl]phenyl]methoxy]phenyl]iminomethyl]-, ethyl ester
  8. Drug

    Nedisertib

    go.drugbank.com/drugs/DB16252
    Investigational

    Nedisertib is under investigation in clinical trial NCT03770689 (Study of M3814 in Combination With Capecitabine and Radiotherapy in Rectal Cancer).

  9. Drug

    Rupitasertib

    go.drugbank.com/drugs/DB15431
    Investigational

    M-2698 is under investigation in clinical trial NCT01971515 (First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies).

  10. Drug

    SYNB1353

    go.drugbank.com/drugs/DB17666
    Investigational

    SYNB1353 is a strain of the probiotic bacteria _Escherichia coli_ (_E. coli_) type Nissle and an engineered probiotic drug. … It is designed to consume methionine in the gastrointestinal tract to prevent its absorption and conversion into homocysteine.[L45983]